ESGO 2024 Insights: "SENTIX Trial - Survival of Patients With Early Stages Cervical Cancer After SLN Biopsy Without Systematic Pelvic Lymphadenectomy" | VuMedi

Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "SENTIX Trial - Survival of Patients With Early Stages Cervical Cancer After SLN Biopsy Without Systematic Pelvic Lymphadenectomy"

By Insights from 2024 ESGO Annual Meeting FEATURING David Cibula

By Insights from 2024 ESGO Annual Meeting FEATURING David Cibula

234 views

April 19, 2024

Comments 0

Login to view comments. Click here to Login